Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing an agreement to deploy Owkin’s K Pro artificial intelligence platform within its drug discovery operations. Following a pilot assessment conducted last year, Boehringer Ingelheim has decided to roll out the agentic “AI Scientist” more broadly across its oncology and immunology research and development (R&D) operations. The K Pro platform is designed to assist scientists and drug developers in analyzing diverse medical data, including complex patient information, using plain language reasoning rather than computer code to explore disease traits, biological patterns, and treatment concepts.
The initial pilot program utilized the $50 million collaborative Multi Omic Spatial Atlas In Cancer (MOSAIC) dataset, which Owkin reports delivered deep spatial insights into the tumor microenvironment of a specific gene target. While the financial terms of the broader rollout have not been disclosed, the agreement demonstrates a shift toward data-driven pharmaceutical research. According to Thomas Clozel, Owkin’s co-founder and co-chief executive, the next decade of drug development will be defined by access to deep multimodal patient data and AI systems like K Pro that are capable of reasoning over that information.
Boehringer Ingelheim’s adoption follows similar moves by other major pharmaceutical groups earlier this year. AstraZeneca secured a three-year license for the platform in May to build custom AI agents for its R&D teams, while Sanofi entered a five-year alliance in June focused on similar objectives. Owkin’s co-CEO Pascal Weinberger indicated that additional partnerships with other pharma groups are expected to be announced shortly. Weinberger noted that the advent of superhuman intelligence is dramatically changing how science is conducted, offering an opportunity to rethink how the industry discovers and brings medicines to market within their drug discovery operations.
